Zacks Investment Research Upgrades Endocyte (ECYT) to Hold
Zacks Investment Research upgraded shares of Endocyte (NASDAQ:ECYT) from a sell rating to a hold rating in a research report report published on Friday morning.
According to Zacks, “In October 2017, Endocyte accelerated its path to commercialization as it acquired the rights to PSMA-617, being evaluated for the treatment of prostate cancer. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company. Currently, the company plans to focus on its most promising programs – lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform. In the last one year, shares of the company have outperformed the industry. However, Endocyte has very few candidates in its pipeline with all of them in the early or mid-stages of development. With no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. Endocyte’s products will face intense competition in the market from both large pharma companies and small and mid-sized companies.”
Separately, ValuEngine lowered Endocyte from a sell rating to a strong sell rating in a report on Thursday, December 21st.
In other news, VP Christopher P. Leamon sold 23,231 shares of Endocyte stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $5.04, for a total value of $117,084.24. Following the transaction, the vice president now directly owns 150,579 shares in the company, valued at $758,918.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Philip S. Low sold 50,511 shares of Endocyte stock in a transaction dated Thursday, December 28th. The stock was sold at an average price of $4.41, for a total value of $222,753.51. Following the completion of the transaction, the insider now owns 354,050 shares in the company, valued at $1,561,360.50. The disclosure for this sale can be found here. Insiders sold 124,253 shares of company stock worth $562,591 over the last quarter. 14.86% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of ECYT. BlackRock Inc. increased its stake in shares of Endocyte by 223.7% in the fourth quarter. BlackRock Inc. now owns 1,138,791 shares of the biopharmaceutical company’s stock worth $4,875,000 after purchasing an additional 786,933 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 393,975 shares during the period. FMR LLC increased its stake in shares of Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after purchasing an additional 31,168 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 25,003 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Endocyte by 46.5% in the fourth quarter. Bank of New York Mellon Corp now owns 51,313 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 16,283 shares during the period. Institutional investors and hedge funds own 17.47% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/02/10/zacks-investment-research-upgrades-endocyte-ecyt-to-hold.html.
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.